May 25, 2021
Daiichi Sankyo’s biosimilar version of Humira (adalimumab) will join the NHI price list on May 26 as the second follow-on of AbbVie’s heavyweight anti-TNF-α antibody in Japan, according to the government’s official gazette issued on May 25. Adalimumab BS Subcutaneous...read more